COO share sale: Kiniksa (KNSA) executive sells 1,703 shares under plan

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc chief operating officer Moat Ross reported an open-market sale of 1,703 Class A Ordinary Shares on April 9, 2026 at $46.69 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan entered on November 13, 2024, and Ross now directly holds 12,029 shares.

Insider Trade Summary 10b5-1

Net Seller: 1,703 shares

Net Sell 1 txn

Insider Moat Ross

Role CHIEF OPERATING OFFICER

Sold 1,703 shs ($80K)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Share	1,703	$46.69	$80K

Holdings After Transaction: Class A Ordinary Share — 12,029 shares (Direct)

Footnotes (1)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024.

Key Figures

Shares sold: 1,703 shares Sale price per share: $46.69 per share Shares held after sale: 12,029 shares +1 more

4 metrics

Shares sold 1,703 shares Class A Ordinary Shares sold on April 9, 2026

Sale price per share $46.69 per share Open-market sale on April 9, 2026

Shares held after sale 12,029 shares Direct ownership following April 9, 2026 transaction

Net shares sold 1,703 shares Net-sell direction in transaction summary

Key Terms

Class A Ordinary Share, open-market sale, Rule 10b5-1 plan, Form 4

4 terms

Class A Ordinary Share financial

"security_title: "Class A Ordinary Share" in the transaction details"

A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.

open-market sale financial

"transaction_action: "open-market sale" describing the transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rule 10b5-1 plan regulatory

"footnote: "pursuant to a 10b5-1 plan executed by the reporting person""

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) heading for the disclosure"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 04/13/2026 - 04:34 PM Learn about SEC filing dates

FAQ

What insider transaction did Kiniksa (KNSA) COO Moat Ross report?

Kiniksa’s COO Moat Ross reported selling 1,703 Class A Ordinary Shares. The sale occurred on April 9, 2026 at a price of $46.69 per share in an open-market transaction, as disclosed in a Form 4 insider filing.

Was the Kiniksa (KNSA) COO share sale made under a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 trading plan. That plan was executed by the reporting person on November 13, 2024, indicating the sale was pre-arranged rather than a spur-of-the-moment trading decision.

How many Kiniksa (KNSA) shares did the COO sell and at what price?

The COO sold 1,703 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc. The reported sale price was $46.69 per share in an open-market transaction on April 9, 2026, according to the Form 4 disclosure.

How many Kiniksa (KNSA) shares does COO Moat Ross hold after this sale?

After the reported sale, Moat Ross directly holds 12,029 Class A Ordinary Shares. This post-transaction holding figure is disclosed in the Form 4 and shows he retains a substantial remaining equity position in Kiniksa.

What type of security did the Kiniksa (KNSA) Form 4 transaction involve?

The transaction involved Kiniksa’s Class A Ordinary Shares, categorized as a non-derivative security. No options or other derivative securities were reported in this filing, and the derivative position summary in the data is empty.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moat Ross

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	04/09/2026		S(1)		1,703	D	$46.69	12,029	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024.

	/s/ Douglas Barry, Attorney-in-Fact	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)